Page last updated: 2024-11-13
hexa-d-arginine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 57358476 |
| SCHEMBL ID | 19267519 |
| MeSH ID | M000605672 |
Synonyms (16)
| Synonym |
|---|
| hexa-d-arginine amide |
| 673202-67-0 |
| d-argininamide, d-arginyl-d-arginyl-d-arginyl-d-arginyl-d-arginyl- |
| hexa-d-arginine , |
| CS-7595 |
| AKOS024458307 |
| n~5~-(diaminomethylidene)-d-ornithyl-n~5~-(diaminomethylidene)-d-ornithyl-n~5~-(diaminomethylidene)-d-ornithyl-n~5~-(diaminomethylidene)-d-ornithyl-n~5~-(diaminomethylidene)-d-ornithyl-n~5~-(diaminomethylidene)-d-ornithinamide |
| DTXSID90724127 |
| furin inhibitor ii |
| SCHEMBL19267519 |
| HY-P1028 |
| NCGC00505008-01 |
| BS-17319 |
| D71119 |
| d-argininamide d-arginyl-d-arginyl-d-arginyl-d-arginyl-d-arginyl-d-alanine |
| d-argininamided-arginyl-d-arginyl-d-arginyl-d-arginyl-d-arginyl-d-alanine |
Research Excerpts
Compound-Compound Interactions
| Excerpt | Reference | Relevance |
|---|---|---|
| " The influence of furin suppression on HBV replication and the effect of CMK combined with nucleoside analog entecavir (ETV) on HBV replication and HBeAg secretion was investigated in HepG2." | ( Entecavir combined with furin inhibitor simultaneously reduces hepatitis B virus replication and e antigen secretion. Gu, L; Li, DM; Peng, XM; Yang, HY; Zheng, NQ, 2014) | 0.4 |
| " Moreover, the viral replication-enhancing effect of CMK was abrogated by ETV and ETV combined with CMK reduced HBV replication and HBeAg secretion simultaneously." | ( Entecavir combined with furin inhibitor simultaneously reduces hepatitis B virus replication and e antigen secretion. Gu, L; Li, DM; Peng, XM; Yang, HY; Zheng, NQ, 2014) | 0.4 |
| " Nucleotide/nucleoside analogs combined with furin inhibitors may be a potential easy way to realize the dual goals of the antiviral therapy for chronic hepatitis B in the future." | ( Entecavir combined with furin inhibitor simultaneously reduces hepatitis B virus replication and e antigen secretion. Gu, L; Li, DM; Peng, XM; Yang, HY; Zheng, NQ, 2014) | 0.4 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (1)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1347149 | Furin counterscreen qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 17.90
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (17.90) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (20.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (80.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||